Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 177

1.

Systematic review: glucose control and cardiovascular disease in type 2 diabetes.

Kelly TN, Bazzano LA, Fonseca VA, Thethi TK, Reynolds K, He J.

Ann Intern Med. 2009 Sep 15;151(6):394-403. Epub 2009 Jul 20. Review.

PMID:
19620144
2.

Effects of intensive glucose control on incidence of cardiovascular events in patients with type 2 diabetes: a meta-analysis.

Zhang CY, Sun AJ, Zhang SN, Wu CN, Fu MQ, Xia G, Wang KQ, Zou YZ, Ge JB.

Ann Med. 2010 May 6;42(4):305-15. doi: 10.3109/07853891003796752.

PMID:
20429797
3.

Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus.

Hemmingsen B, Lund SS, Gluud C, Vaag A, Almdal T, Hemmingsen C, Wetterslev J.

Cochrane Database Syst Rev. 2011 Jun 15;(6):CD008143. doi: 10.1002/14651858.CD008143.pub2. Review. Update in: Cochrane Database Syst Rev. 2013;11:CD008143.

PMID:
21678374
4.

The effect of interventions to prevent cardiovascular disease in patients with type 2 diabetes mellitus.

Huang ES, Meigs JB, Singer DE.

Am J Med. 2001 Dec 1;111(8):633-42.

PMID:
11755507
6.

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.

ADVANCE Collaborative Group., Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F.

N Engl J Med. 2008 Jun 12;358(24):2560-72. doi: 10.1056/NEJMoa0802987. Epub 2008 Jun 6.

7.

Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus.

Hemmingsen B, Lund SS, Gluud C, Vaag A, Almdal TP, Hemmingsen C, Wetterslev J.

Cochrane Database Syst Rev. 2013 Nov 11;(11):CD008143. doi: 10.1002/14651858.CD008143.pub3. Review. Update in: Cochrane Database Syst Rev. 2015;(7):CD008143.

PMID:
24214280
8.

Systematic review on urine albumin testing for early detection of diabetic complications.

Newman DJ, Mattock MB, Dawnay AB, Kerry S, McGuire A, Yaqoob M, Hitman GA, Hawke C.

Health Technol Assess. 2005 Aug;9(30):iii-vi, xiii-163. Review.

9.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
10.

Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials.

Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, Lafont S, Bergeonneau C, Kassaï B, Erpeldinger S, Wright JM, Gueyffier F, Cornu C.

BMJ. 2011 Jul 26;343:d4169. doi: 10.1136/bmj.d4169. Review.

11.

Intensive insulin therapy and mortality among critically ill patients: a meta-analysis including NICE-SUGAR study data.

Griesdale DE, de Souza RJ, van Dam RM, Heyland DK, Cook DJ, Malhotra A, Dhaliwal R, Henderson WR, Chittock DR, Finfer S, Talmor D.

CMAJ. 2009 Apr 14;180(8):821-7. doi: 10.1503/cmaj.090206. Epub 2009 Mar 24. Review.

12.

Effect of tight blood glucose control versus conventional control in patients with type 2 diabetes mellitus: a systematic review with meta-analysis of randomized controlled trials.

Buehler AM, Cavalcanti AB, Berwanger O, Figueiro M, Laranjeira LN, Zazula AD, Kioshi B, Bugano DG, Santucci E, Sbruzzi G, Guimaraes HP, Carvalho VO, Bordin SA.

Cardiovasc Ther. 2013 Jun;31(3):147-60. doi: 10.1111/j.1755-5922.2011.00308.x. Epub 2011 Dec 29. Review.

PMID:
22212499
13.

Risk for nocturnal hypoglycemia with biphasic insulin aspart 30 compared with biphasic human insulin 30 in adults with type 2 diabetes mellitus: a meta-analysis.

Davidson JA, Liebl A, Christiansen JS, Fulcher G, Ligthelm RJ, Brown P, Gylvin T, Kawamori R.

Clin Ther. 2009 Aug;31(8):1641-51. doi: 10.1016/j.clinthera.2009.08.011.

PMID:
19808125
14.

Intensive glucose control and cardiovascular outcomes in type 2 diabetes.

Macisaac RJ, Jerums G.

Heart Lung Circ. 2011 Oct;20(10):647-54. doi: 10.1016/j.hlc.2010.07.013. Epub 2010 Aug 31. Review.

PMID:
20807681
15.

Prevention of cardiovascular disease through glycemic control in type 2 diabetes: a meta-analysis of randomized clinical trials.

Mannucci E, Monami M, Lamanna C, Gori F, Marchionni N.

Nutr Metab Cardiovasc Dis. 2009 Nov;19(9):604-12. doi: 10.1016/j.numecd.2009.03.021. Epub 2009 May 8.

PMID:
19427768
16.

Intensive glucose control and macrovascular outcomes in type 2 diabetes.

Control Group., Turnbull FM, Abraira C, Anderson RJ, Byington RP, Chalmers JP, Duckworth WC, Evans GW, Gerstein HC, Holman RR, Moritz TE, Neal BC, Ninomiya T, Patel AA, Paul SK, Travert F, Woodward M.

Diabetologia. 2009 Nov;52(11):2288-98. doi: 10.1007/s00125-009-1470-0. Epub 2009 Aug 5. Erratum in: Diabetologia. 2009 Nov;52(1):2470. Control Group [added].

PMID:
19655124
17.

Addition of thiazolidinedione or exenatide to oral agents in type 2 diabetes: a meta-analysis.

Pinelli NR, Cha R, Brown MB, Jaber LA.

Ann Pharmacother. 2008 Nov;42(11):1541-51. doi: 10.1345/aph.1L198. Epub 2008 Oct 28.

PMID:
18957626
18.

Glycemic targets for patients with type 2 diabetes mellitus.

Hamnvik OP, McMahon GT.

Mt Sinai J Med. 2009 Jun;76(3):227-33. doi: 10.1002/msj.20117.

19.

Early and intensive therapy for management of hyperglycemia and cardiovascular risk factors in patients with type 2 diabetes.

Dailey G.

Clin Ther. 2011 Jun;33(6):665-78. doi: 10.1016/j.clinthera.2011.04.025. Review.

PMID:
21704233
20.

Effect of Intensive Versus Standard Blood Glucose Control in Patients With Type 2 Diabetes Mellitus in Different Regions of the World: Systematic Review and Meta-analysis of Randomized Controlled Trials.

Sardar P, Udell JA, Chatterjee S, Bansilal S, Mukherjee D, Farkouh ME.

J Am Heart Assoc. 2015 May 5;4(5). pii: e001577. doi: 10.1161/JAHA.114.001577. Review.

Supplemental Content

Support Center